Sytrinol cholesterol alternative

Agenda• Welcome and Thank You!

• Setting the Stage

• Cholesterol and heart health

• The challenge

• The natural solution

• Sytrinol proven benefits

Sytrinol® Condition Specific Strategy

• Heart Health

• Eye Health

• Joint Health

• Sports Performance

SourceOne’s strategic approach to the market focuses on product concepts that support specific aspects of human health.

• Weight Loss

• Metabolic Syndrome

• Type II Diabetes

Primary focus is to help our customers create formulations to address these health concerns and then market them creatively

Cardiovascular Health

• More than 64 million Americans have some form of CVD• Estimated 1 in 4 deaths in the US each year from heart

disease• Leading cause of death in the US each year since 1900• CVD will cost the nation over an estimated $386 billion in • High blood cholesterol is one of the major risk factors for

Heart Disease

Breaking News from the American Heart Association…

• The American Heart Association’s new guidelines for preventing CVD in women includes a strong recommendation that high-risk women, even those with an LDL cholesterol level below 100, should receive cholesterol-lowering statin drugs

• In 2012, 56 percent of women identified heart disease as the leading cause of death compared with 30 percent in 1997

Recommendations endorsed by: • National Heart, Lung and Blood Institute• American Heart Association • American College of Cardiology

“Experts Set a Lower Low for Cholesterol Levels”

The new guidelines are also expected to TRIPLE the number of people prescribed a cholesterol lowering drug - from 15

million to more than 36 million!

Six of nine panel members drafting new guideline are associatedwith companies that manufacture statins

New NCEP-ATP III (2001)*Earlier NCEP-ATP II (1993)*

High≥60

Low<40Optimal>35HDL-cholesterol

High≥240>260

Borderline200-239Borderline220-260

Desirable<200Optimal<220Total cholesterol

Very High≥190

High160-189

Borderline130-159High>160

Near optimal

100-129Borderline130-159

Optimal<100Optimal<130LDL-cholesterol

New NCEP-ATP III (2001)*Earlier NCEP-ATP II (1993)*

High≥60

Low<40Optimal>35HDL-cholesterol

High≥240>260

Borderline200-239Borderline220-260

Desirable<200Optimal<220Total cholesterol

Very High≥190

High160-189

Borderline130-159High>160

Near optimal

100-129Borderline130-159

Optimal<100Optimal<130LDL-cholesterol

Cholesterol-lowering Options

• New NCEP guidelines expected to raise the number of people on dietary treatment from about 52 million to about 65 million.

• The guidelines are also expected to TRIPLE the number of people prescribed a cholesterol lowering drug - from 15 million to 36 million.

• More aggressive cholesterol-lowering treatment• Better identification of those at high risk for a heart attack• Use of a lipoprotein profile as the first test for high cholesterol• A new level at which low HDL becomes a major heart disease risk factor• A new set of Therapeutic Lifestyle Changes with more power to improve cholesterol levels

NCEP ATP III– Besides the new lipid numbers, what are other changes?

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

SytrinolNature’s Solution to the Cholesterol Problem

• A patented formula derived from natural citrus and palm fruit extracts.

• Combines polymethoxylated flavones (PMFs) & palm alpha, delta, and gamma tocotrienols, and other proprietary constituents.

• Supported by multiple clinical studies• Efficacious dose is 300mg per day

Orange, Tangerine Peels Could Be Better Than Drugs For Lowering Cholesterol

Journal of Agricultural and Food Chemistry, May 2004

The most common of these super-flavonoids tangeretin and nobiletin - exist in orange and tangerine peels. Easier way to lower cholesterolThan drinking 20 or more cups of orange juice daily

“A joint study by the U.S. Department of Agriculture and KGK Synergize, identified a class of compounds isolated from orange and tangerine peels that shows promise in animal studies as a potent, natural alternative for lowering LDL cholesterol (bad cholesterol), without the possible side effects, such as liver disease and muscle weakness, of conventional cholesterol-lowering drugs.”

Sytrinol Animal Study• Male Golden Syrian Hamsters, initial body weight 100-120g• Control and experimental diets for 35 days• Treatments included Sytrinol, PMF, Tocotrienol, others• Serum analyzed for lipid responses

TC – Total CholesterolLDL – LDL CholesterolTG – Total Triglyceride

TC LDL TG

% c

han

ge f

rom

B

asel

ine

to 5

-wee

ks

-80%

-70%

-60%-50%

-40%

-30%

-20%

-10%

0%

-50% -59% -57%

* * *

* P 0.05

Kurowska et al., 2004

4-week clinical results

-35%

-30%

-25%

-20%

-15%

-10%

-5%

0%TC LDL TG LDL / HDL

I ΙΙ ΙΙΙ I ΙΙ ΙΙΙ I ΙΙ ΙΙΙ I ΙΙ ΙΙΙ

Multiple Clinical Study Summary

% r

edu

ctio

n

Effect on Total Cholesterol

BASELINE 4 WEEK 8 WEEK 12 WEEK

-29% -28% -30%

200

210

220

230

240

250

260

270

280

290

300

-29% -28% -30%

PLACEBO/SYTRINOL

* **

mg/

dL * P 0.05

* Published in Alternative Therapies for Health and Medicine

150

160

170

180

190

200

210

Effect on LDL Cholesterol


-25% -25% -27%

* **

mg/

dL

PLACEBO/SYTRINOL

* P 0.05


Effect on Total Triglyceridem

g/dL

60

70

80

90

100

110

120


-30% -35% -34%

* **

PLACEBO/SYTRINOL

* P 0.05


3

3.5

4

4.5

5

LDL/HDL


-30% -28% -29%

* **

PLACEBO/SYTRINOL

Rat

io o

f L

DL

:HD

L


Heart Protection Matrix

LDL benefits (PMFs)•Reduced ApoB => Reduced LDL synth.•Reduced MTTP => Reduced LDL synth.

MTTP = microsomal triglyceride transer protein; DGAT = diacylglycerol acteyl transferasePPAR = peroxisome proliferator-activated receptor; HMGCAR = HMGCoA Reductase

Antioxidant benefits (both)

Anti-inflammatory benefits(PMFs)

TC benefits (Tocotrienols)•Increased HMGCAR degradation => Reduced TC synth.

Triglyceride benefits (PMFs)•Reduced DGAT => Reduced TG synth.

•Increased liver PPAR => Increased FA oxid.

Fatty acids Triglycerides

DGAT

LDL Lipoprotein Assembly

Fatty Acids TriglyceridesX

Triglycerides Nascent apo B

MTP

X

Kurowska et al.,2004

ß-oxPPARFatty acids

PMF Mechanism

ACETYL COA

HMG-CoA Reductase

GERANYL GERANIO

GERANIOL

FARNESOL

PROTEINS CoQ10

CHOLESTEROL

CHOLESTEROLSYNTHESIS

CoQ10 ↓ by statinMay lead to ↓ energy

Protein ↓ by statinMay lead to myopathy

STATIN

X

TOCOTRIENOL

(Targets Farnesol)

Down RegulatesHMGCR

HMGCR-INCREASE RATEOF NATURALDEGRADATION

HMG-CoA REDUCTASE

Sytrinol as the Superior Product

Sytrinol vs. Guggulipids• Journal of the American Medical Association states that

consuming guggulipids does not have any significant effect on lowering cholesterol.

• Studies have shown guggulipids to actually raise levels of LDL cholesterol.

• University of Kansas found that guggulsterone, the active ingredient in guggulipid, may interfere with nearly 60% of prescribed drugs, ironically enough, including anti-cholesterol statin drugs.

• Mayo Clinic Health Letter and John Hopkins Med Letter reported guggulipids were not effective for lowering cholesterol.

Guggulipids vs.

Reduces Arterial Plaque NO Reduces Inflammation NO Strong Antioxidant Activity NO Continued investement in clinical research

NO Researched ingredient available to consumer

Varies % TC reduced 12% 30%

% LDL reduced 13% 27%

%TG reduced 12% 34%

% HDL increased None Reported 4%

Potency used in trials2,000-6,000 mg Guggul 50-

150mg Guggulsterones 300 mg

Dosage recommended in supplements

600 mg Guggul 12.5mg Guggulsterones 300mg /day

Guggulipids vs.

Mechanisms of Action

Inhibition of cholesterol biosynthesis, enhancement rate

of cholesterol extraction and promotion of degradation of

cholesterol

Inhibits HMG-COA reductase, decreases Apo protein B needed for LDL synthesis,

decreases activity DGAT, enzyme needed for TG synthesis

Adverse Side Effects Reported Headache, nausea, skin rash None Reported. Well Tolerated

Drug InteractionsUniversity of Kansas reports it

interacts with 60% of prescription drugs

None Reported. Well Tolerated

Sytrinol vs. Policosanol• No clinical trials supporting the efficacy of policosanol

outside of Cuba• Journal of American Medical Association finds no

evidence of a lipid-lowering benefit with policosanol.• “The evidence base supporting policosanol has eroded

dramatically since its global birth at the turn of the 21st century. The ostensible promise and the eventual disappointment underscore the need for independent RCTs, and for multi-ethnic interventions.” - Anthony Almada MSc

Policosanol vs.

Reduces Arterial Plaque NO Reduces Inflammation NO Strong Antioxidant Activity

NO Continued investement in clinical research

NO Researched ingredient available to consumer

NO % TC reduced 16% 30%

% LDL reduced 10-20% 27%

%TG reduced Minimal Effect 34%

% HDL increased 5-25% 4%

Potency used in trials 10-40 mg 300 mg


10-40 mg/day 300mg /day

Mechanisms of Action No agreement on mechanism of action

Inhibits HMG-COA reductase, decreases Apo protein B needed for

LDL synthesis, decreases activity DGAT, enzyme needed for TG

synthesis

Adverse Side Effects Reported

Weight loss, frequent urination, headache, dizziness, others None Reported. Well Tolerated

Drug InteractionsDo not mix well with blood thinning

medications or aspirin None Reported. Well Tolerated

Policosanol vs.

Sytrinol vs. Plant Sterols

• Plant sterols do not reduce arterial plaque or inflammation.

• Plant sterols cannot be used for strong antioxidant activity.

• Plant sterols have no effect on triglyceride levels or HDL levels.

Plant Sterols vs.

Reduces Arterial Plaque NO Reduces Inflammation NO Strong Antioxidant Activity NO Continued investement in clinical research

NO Researched ingredient available to consumer % TC reduced 8-15% 30%

% LDL reduced 8-15% 27%

%TG reduced NO 34%

% HDL increased NO 4%

Potency used in trials 800-3,000mg 300 mg


800-1800mg 300mg /day

Plant Sterols vs.

Mechanisms of ActionBlock food based cholesterol from being absorbed into the

bloodstream

Inhibits HMG-COA reductase, decreases Apo protein B needed for

LDL synthesis, decreases activity DGAT, enzyme needed for TG

synthesis

Adverse Side Effects Reported

No knows drug or nutrient reactions, some GI upset in

one studyNone Reported. Well Tolerated

Drug Interactions None None Reported. Well Tolerated

Health & Medicine

Sytrinol cholesterol alternative